GERN
GERN clinical trials: GERON CORP
Every trial on ClinicalTrials.gov where GERON CORP is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 24
- Trials linked
- 17
- As lead sponsor
- 7
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
GERN on the catalyst calendar · GERN registry changes
- Primary completion Jul 2030Sponsor estimatePhase 4NCT07939451A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS)Geron Corporation · MDS (Myelodysplastic Syndrome)Not yet recruitingGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimatePhase 1NCT05371964A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib...Geron Corporation · MyelofibrosisActive, not recruitingGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2028Sponsor estimatePhase 3NCT04576156A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have...Geron Corporation · MyelofibrosisActive, not recruitingGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2023ActualPhase 2/Phase 3NCT02598661Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk...Geron Corporation · Myelodysplastic SyndromesActive, not recruitingGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2014ActualPhase 2NCT01242930Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple MyelomaGeron Corporation · Multiple MyelomaCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05937568Expanded Access for Treatment With ImetelstatGeron Corporation · Myelodysplastic SyndromesApproved for marketingGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 24, 2018ActualPhase 2NCT01731951Imetelstat Sodium in Treating Participants With Primary or Secondary MyelofibrosisGeron Corporation · Primary MyelofibrosisCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 26, 2018ActualPhase 2NCT02426086Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously...Geron Corporation · MyelofibrosisCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2012ActualPhase 2NCT01256762Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast CancerGeron Corporation · Locally Recurrent or Metastatic Breast CancerCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2013ActualPhase 2NCT01243073Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia VeraGeron Corporation · Essential ThrombocythemiaCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2013ActualPhase 2NCT01137968Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)Geron Corporation · Non-small Cell Lung CancerCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2011ActualPhase 1NCT00732056A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast CancerGeron Corporation · Breast CancerCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2011ActualPhase 1NCT00718601Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed MyelomaGeron Corporation · Multiple MyelomaCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2011ActualPhase 1NCT00594126Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple MyelomaGeron Corporation · Multiple MyelomaCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2011ActualPhase 1NCT00510445Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung CancerGeron Corporation · Lung CancerCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2013ActualPhase 1NCT00310895Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor MalignanciesGeron Corporation · Solid Tumor MalignanciesCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2013ActualPhase 1NCT00124189Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)Geron Corporation · Chronic Lymphoproliferative DiseasesCompletedGERNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2027Sponsor estimatePhase 2NCT07549451Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative NeoplasmsM.D. Anderson Cancer Center · Phase IINot yet recruitingGERNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2031Sponsor estimatePhase 1NCT07909733Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCTUniversity of Wisconsin, Madison · High-risk Myeloid MalignancyNot yet recruitingGERNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 27, 2025ActualPhase 2NCT05583552Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based TherapyGCP-Service International West GmbH · Myelodysplastic SyndromesCompletedGERNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2028Sponsor estimatePhase 1NCT06247787A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That...Children's Oncology Group · Recurrent Childhood Acute Myeloid LeukemiaRecruitingGERNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2030Sponsor estimatePhase 1NCT07320235Imetelstat Combinations in Relapsed AMLDouglas Tremblay · Relapsed Acute Myeloid LeukemiaRecruitingGERNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2013ActualPhase 1NCT01916187Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With NeuroblastomaNCIC Clinical Trials Group · NeuroblastomaWithdrawnGERNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2012ActualPhase 1NCT01265927A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast CancerIndiana University · Breast NeoplasmsCompletedGERNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 24 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner